郑州大学学报(医学版)
鄭州大學學報(醫學版)
정주대학학보(의학판)
JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES)
2015年
4期
453-457
,共5页
杨露%张楠楠%张彦婷%李庆华%许尧%朱相展%薛乐勋%关方霞
楊露%張楠楠%張彥婷%李慶華%許堯%硃相展%薛樂勛%關方霞
양로%장남남%장언정%리경화%허요%주상전%설악훈%관방하
Ets2%增殖%侵袭%细胞周期%凋亡%EC9706 细胞
Ets2%增殖%侵襲%細胞週期%凋亡%EC9706 細胞
Ets2%증식%침습%세포주기%조망%EC9706 세포
Ets2%proliferation%invasion%cell cycle%apoptosis%EC9706 cell
目的::探讨 Ets2 siRNA 转染对 EC9706细胞增殖、侵袭能力、周期和凋亡的影响。方法:利用 Western blot检测正常食管上皮细胞系 Het-1A 和食管鳞状细胞癌细胞系(EC1、Eca109、EC9706)中 Ets2蛋白的表达。将 EC9706细胞分为4组:阴性对照组、空白对照组、转染试剂对照组和 Ets2 siRNA 组,处理48 h 后,采用 EdU 荧光标记法和CCK-8法检测4组细胞增殖率和增殖抑制率,Transwell 小室法检测细胞侵袭能力,Western blot 检测 E-cadherin、Caspase-3和 Bcl-2蛋白的表达情况,流式细胞仪检测细胞周期,Annexin V-FITC/ PI 双染法检测早期细胞凋亡。结果:与 Het-1A 细胞相比,EC1、Eca109和 EC9706细胞中 Ets2蛋白的表达量增加(F =1177.764,P <0.001),且EC9706细胞中增加最为显著。转染后,与阴性对照组相比,Ets2 siRNA 组细胞增殖率降低、增殖抑制率升高(F =64.733和144.741,P <0.05),侵袭能力减弱(F =104.065,P <0.001),细胞周期无明显变化(P >0.05),早期凋亡细胞增加(F =37.986,P <0.001),E-cadherin 蛋白和 Caspase-3蛋白表达增加(F =62.223和81.015,P <0.05),而Bcl-2蛋白表达减少(F =104.439,P <0.001)。结论:Ets2下调后能有效抑制 EC9706细胞增殖,降低侵袭能力,诱导凋亡;Ets2可能成为食管鳞状细胞癌的有效治疗靶点。
目的::探討 Ets2 siRNA 轉染對 EC9706細胞增殖、侵襲能力、週期和凋亡的影響。方法:利用 Western blot檢測正常食管上皮細胞繫 Het-1A 和食管鱗狀細胞癌細胞繫(EC1、Eca109、EC9706)中 Ets2蛋白的錶達。將 EC9706細胞分為4組:陰性對照組、空白對照組、轉染試劑對照組和 Ets2 siRNA 組,處理48 h 後,採用 EdU 熒光標記法和CCK-8法檢測4組細胞增殖率和增殖抑製率,Transwell 小室法檢測細胞侵襲能力,Western blot 檢測 E-cadherin、Caspase-3和 Bcl-2蛋白的錶達情況,流式細胞儀檢測細胞週期,Annexin V-FITC/ PI 雙染法檢測早期細胞凋亡。結果:與 Het-1A 細胞相比,EC1、Eca109和 EC9706細胞中 Ets2蛋白的錶達量增加(F =1177.764,P <0.001),且EC9706細胞中增加最為顯著。轉染後,與陰性對照組相比,Ets2 siRNA 組細胞增殖率降低、增殖抑製率升高(F =64.733和144.741,P <0.05),侵襲能力減弱(F =104.065,P <0.001),細胞週期無明顯變化(P >0.05),早期凋亡細胞增加(F =37.986,P <0.001),E-cadherin 蛋白和 Caspase-3蛋白錶達增加(F =62.223和81.015,P <0.05),而Bcl-2蛋白錶達減少(F =104.439,P <0.001)。結論:Ets2下調後能有效抑製 EC9706細胞增殖,降低侵襲能力,誘導凋亡;Ets2可能成為食管鱗狀細胞癌的有效治療靶點。
목적::탐토 Ets2 siRNA 전염대 EC9706세포증식、침습능력、주기화조망적영향。방법:이용 Western blot검측정상식관상피세포계 Het-1A 화식관린상세포암세포계(EC1、Eca109、EC9706)중 Ets2단백적표체。장 EC9706세포분위4조:음성대조조、공백대조조、전염시제대조조화 Ets2 siRNA 조,처리48 h 후,채용 EdU 형광표기법화CCK-8법검측4조세포증식솔화증식억제솔,Transwell 소실법검측세포침습능력,Western blot 검측 E-cadherin、Caspase-3화 Bcl-2단백적표체정황,류식세포의검측세포주기,Annexin V-FITC/ PI 쌍염법검측조기세포조망。결과:여 Het-1A 세포상비,EC1、Eca109화 EC9706세포중 Ets2단백적표체량증가(F =1177.764,P <0.001),차EC9706세포중증가최위현저。전염후,여음성대조조상비,Ets2 siRNA 조세포증식솔강저、증식억제솔승고(F =64.733화144.741,P <0.05),침습능력감약(F =104.065,P <0.001),세포주기무명현변화(P >0.05),조기조망세포증가(F =37.986,P <0.001),E-cadherin 단백화 Caspase-3단백표체증가(F =62.223화81.015,P <0.05),이Bcl-2단백표체감소(F =104.439,P <0.001)。결론:Ets2하조후능유효억제 EC9706세포증식,강저침습능력,유도조망;Ets2가능성위식관린상세포암적유효치료파점。
Aim: To investigate the effect of siRNA-mediated down-regulation of Ets2 on the proliferation, invasion, cell cycle and apoptosis of EC9706 cells in vitro. Methods: The expression of Ets2 in Het-1A, EC1, Eca109,and EC9706 cells was analyzed by Western blot. EC9706 cells were allocated into 4 groups: negative control group, blank control group, siRNA control group, and Ets2 siRNA group. The proliferation of EC9706 cells was examined by EdU method and CCK-8 method; the invasion was analyzed by Transwell; cell cycle was studied by flow cytometry; apoptosis was analyzed by Annexin V-FITC/ PI flow cytometry and the protein expressions of E-cadherin,Caspase-3 and Bcl-2 were detected by Western blot. Results: Compared with Het-1A cells, Ets2 showed higher expression in EC1,Eca109,and EC9706 cells (F = 1 177. 764,P < 0. 001), especially in EC9706 cells. Compared with negative control group,the proliferation rate of EC9706 cells decreased and the inhibition rate increased significantly(F = 64. 733,144. 741,P < 0. 05). The number of in-vasion cells was lower in Ets2 siRNA group than that of the negative control group(F = 104. 065,P < 0. 001). The cell cy-cle among the 4 groups had no obvious change(P > 0. 05). Compared with the negative control group , Ets2 siRNA group had a higher apoptosis rate(F = 37. 986,P < 0. 001). The protein expression levels of E-cadherin and Caspase-3 increased significantly(F = 62. 223,81. 015,P < 0. 05) and the Bcl-2 protein expression level decreased obviously(F = 104. 439,P <0. 001). Conclusion: siRNA-mediated down-regulation of Ets2 could effectively inhibit the proliferation of EC9706 cells, decrease the invasion and induce the apoptosis. Therefore, Ets2 may be a potential therapeutic target for ESCC.